Premium
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
Author(s) -
Xu XS,
Yan X,
Puchalski T,
Lonial S,
Lokhorst HM,
Voorhees PM,
Plesner T,
Liu K,
Khan I,
Jansson R,
Ahmadi T,
Ruixo JJ Perez,
Zhou H,
Clemens PL
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.577
Subject(s) - daratumumab , regimen , medicine , pharmacokinetics , multiple myeloma , oncology , refractory (planetary science) , pharmacology , lenalidomide , physics , astrobiology
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen for daratumumab is challenging due to its target‐mediated drug disposition, leading to time‐ and concentration‐dependent pharmacokinetics. We describe a thorough evaluation of the recommended dose regimen for daratumumab in patients with relapsed or refractory MM.